BMO Capital Slashes Novo Nordisk Price Target to $105
BMO Capital cuts Novo Nordisk price target from $156 to $105. Explore the reasons behind this significant downgrade. Stay updated with financial insights.
Topic
BMO Capital
A collection of 1 issue